← Back to Search

Wnt Inhibitor

LGK974 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with specified cutaneous melanoma conditions are eligible for LGK974 with PDR001 dose expansion
Patients with specified cancers previously treated with anti-PD-1 therapy and whose best response was progressive disease are eligible for LGK974 with PDR001 dose escalation
Screening 3 weeks
Treatment Varies
Follow Up 61 months
Awards & highlights

Study Summary

This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.

Who is the study for?
Adults with advanced cancers like melanoma, cervical, esophageal, colorectal, and breast cancer that have worsened despite treatment or lack a standard therapy. Eligible participants include those with certain genetic mutations or who've had specific prior treatments. People with heart issues, bone diseases, other active cancers, untreated brain metastases, severe autoimmune conditions or allergies to monoclonal antibodies can't join.Check my eligibility
What is being tested?
The trial is testing the safety and optimal dosing of LGK974 alone and combined with PDR001 in patients. It aims to determine how well these drugs can be tolerated by individuals whose cancers are reliant on Wnt ligands for growth and who have exhausted other treatment options.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as inflammation in various organs; gastrointestinal disturbances which could affect drug absorption; bone-related issues; and possibly increased susceptibility to infections due to immune response alterations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have a specific type of skin cancer eligible for a certain treatment.
My cancer worsened after anti-PD-1 therapy, so I can try LGK974 with PDR001.
My advanced cancer has worsened despite treatment, or there's no effective treatment for it.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~61 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 61 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated
Secondary outcome measures
Absorportion and plasma concentrations of PDR001
Absorption and plasma concentrations of LGK974
Overall response rate of tumor
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: LGK974 in combination with PDR001Experimental Treatment2 Interventions
LGK in combination with PDR001
Group II: LGK974Experimental Treatment1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,855 Previous Clinical Trials
4,197,165 Total Patients Enrolled
88 Trials studying Breast Cancer
37,812 Patients Enrolled for Breast Cancer

Media Library

LGK974 (Wnt Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01351103 — Phase 1
Breast Cancer Research Study Groups: LGK974, LGK974 in combination with PDR001
Breast Cancer Clinical Trial 2023: LGK974 Highlights & Side Effects. Trial Name: NCT01351103 — Phase 1
LGK974 (Wnt Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01351103 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this particular clinical trial the inaugural experiment of its genre?

"Since 2011, there have been 27 active trials for LGK974 conducted in 35 countries and 122 cities. This is due to Novartis Pharmaceuticals sponsoring the first trial of 185 patients back in 2011 which ultimately lead to Phase 1 drug approval."

Answered by AI

What potential risks or side effects have been identified regarding LGK974?

"Despite limited evidence of efficacy and safety, our assessment at Power has placed LGK974 on the low end of the scale with a score of 1."

Answered by AI

Are there any historical precedents for LGK974's use in medical experiments?

"LGK974 was first trialled at UCLA School of Medicine in 2011, and 21 studies have been concluded since then. There are now 27 ongoing clinical trials with a notable portion being conducted from Montreal, Quebec."

Answered by AI

What is the current capacity for participants in this experiment?

"This clinical trial, backed by Novartis Pharmaceuticals, necessitates 185 participants who fit the pre-determined criteria. It will be based in Montreal and Houston, with two sites respectively located at Novartis Investigative Site and University of Texas/MD Anderson Cancer Center MD Anderson 2."

Answered by AI

Are there any open vacancies remaining in the clinical trial?

"The details hosted on clinicaltrials.gov demonstrate that this research study is currently accepting participants, having been initially published in December 2011 and last updated at the end of September 2022."

Answered by AI

Are there ample research centers implementing this project in North America?

"Participating in this medical research is 5 sites, including Novartis Investigative Site located in Montreal, University of Texas/MD Anderson Cancer Center MD Anderson 2 and Sidney Kimmel Comprehensive Cancer Center Johns Hopkins situated in Houston and Baltimore respectively. A further 5 locations are also engaging with the clinical trial."

Answered by AI
~14 spots leftby Apr 2025